Calgent was granted orphan drug designation of CAL056 mesylate by the U.S. Food and Drug Administration (FDA) on Feb 28, 2019. Orphan drug designation is an important milestone for CAL056 mesylate, as it will provide marketing exclusivity and economic benefits upon drug approval.
